NEW YORK (GenomeWeb News) - Molecular diagnostics company BG Medicine will collaborate with researchers in Denmark and use data from various cohort studies conducted in Copenhagen in its High Risk Plaque Initiative, the company said today.
The HRP is a research initiative begun by BG Medicine, Merck, AstraZeneca, and Philips that aims to develop diagnostic biomarkers that can predict heart attacks caused by myocardial infarction or by the rupture of atherosclerotic plaque as early as four years before they occur.
Beginning in March, the multiple-phase research program will use BG Medicine’s proteomic and metabolomics discovery capabilities on samples from the Copenhagen City Heart Study, the Copenhagen General Population Study, and other studies, the company said.
"This research is an excellent example of how plasma samples from large-scale epidemiological studies can be used for the discovery and development of novel in-vitro diagnostics to address a significant unmet medical need,” said Borge Nordestgaard, who is chairman of the CGPS and a principal investigator on the collaboration with BG.
BG Medicine CEO Pieter Muntendam characterized the collaboration as a “complement to the other atherosclerosis-related research projects that we are conducting as part of the broader, collaborative HRP Initiative."